ECS Botanics to Release OzSun 2g All-In-One Vape Range in August 2026

Strategic Launch of Larger-Format OzSun Vape Products

ECS Botanics is broadening its OzSun brand with two all-in-one rechargeable vape products, marking a strategic entry into larger-format offerings within Australia's medicinal cannabis market. The 2g vapes significantly differentiate from the prevalent 1g formats, providing enhanced value per gram to healthcare practitioners and patients accessing cannabis via prescription. Manufactured and currently in final packaging stages, the products are on track for a mid-August 2026 launch, with all necessary Australian import approvals secured.

The formulations combine three cannabinoids in tri-blend rosin and distillate blends, aligned with OzSun's Day and Night product lines. The Day variant contains CBG, while the Night includes CBN, both incorporating native cannabis terpenes. ECS emphasizes that these formulations are developed without specific therapeutic claims and comply fully with Australia's prescription medicinal cannabis regulations.

Capital-Efficient Supply via Canadian GMP Manufacturer Ichor Inc

Supply of the new OzSun vape products is secured through a consignment agreement with Ichor Inc, a Canadian GMP-licensed medicinal cannabis manufacturer. This arrangement offers ECS a capital-efficient approach to introducing the new category without upfront inventory investment or significant capital expenditure. Costs are primarily payable as inventory sells, enabling ECS to scale orders based on market demand and sales performance in Australia.

This consignment model aligns with ECS's disciplined portfolio expansion strategy, leveraging existing distribution and Medical Science Liaison resources without requiring additional capital. Pricing and landed costs suggest gross margins comparable to ECS's AVANI branded products, indicating strong potential profitability. This approach allows ECS to gauge market reception before scaling production.

Innovative Integrated Rechargeable Vape Design with USB-C Charging

The OzSun all-in-one vape features an integrated design combining reservoir, battery, heating system, and mouthpiece in a single inhalation-activated device. This eliminates the need for separate batteries typical of 510-thread cartridges, offering a ready-to-use format post-dispensing. The device includes a proprietary ceramic heating core and recharges via USB-C, enhancing user convenience for healthcare practitioners and patients compared to multi-component systems.

With a 2g fill volume, the product offers twice the capacity of common 1g vapes in Australia's medicinal cannabis market, delivering superior value per gram. This larger format reflects trends from mature North American markets, where BDSA data shows disposable vape sales rose 41% over 12 months to May 2026, driven by larger 2g products. The rechargeable, integrated design and increased capacity position OzSun as a differentiated offering in Australia.

Vape Products: Major Cannabis Categories in US and Canada

International data highlights vape products as significant categories in mature North American cannabis markets, providing strategic context for ECS's expansion. BDSA retail sales data for the 12 months to May 2026 indicates vapes accounted for about 26% of US legal cannabis sales, generating approximately US$8 billion, a 6% increase year-over-year. Vapes rank as the second-largest cannabis product category in the US, demonstrating strong consumer adoption.

Within this category, disposable vapes showed 41% sales growth, with larger-format 2g products identified as key drivers of value and category growth. While ECS does not use North American data to forecast Australian demand, the maturity of these markets supports the rationale for introducing larger-format integrated vapes under the OzSun brand. This context underscores vape products' established status in regulated markets with mature distribution, paralleling Australia's prescription medicinal cannabis framework.

OzSun Day and Night Tri-Blend Formulations Featuring Native Cannabis Terpenes

The new all-in-one vapes utilize tri-blend formulations extending OzSun's brand into inhalation delivery. Each 2g product combines rosin and distillate blends manufactured in Canada, incorporating native cannabis terpenes. The Day formula contains cannabigerol (CBG), while the Night includes cannabinol (CBN), offering differentiated options aligned with daytime and evening use.

This tri-blend approach balances full-spectrum rosin benefits with the potency and consistency of distillate, while native terpenes preserve the plant's aromatic and potential therapeutic qualities. ECS developed these formulations without therapeutic claims, ensuring compliance with Australian therapeutic goods regulations and the medicinal cannabis prescription framework. Products will be supplied to qualified healthcare practitioners and patients via established regulatory pathways.

Mid-August 2026 Launch via Established Distribution Channels

The OzSun all-in-one vape range is planned for mid-August 2026 launch through ECS's existing Australian medicinal cannabis distribution network, seamlessly extending the company’s commercial infrastructure. Launch timing depends on final packaging, importation, and standard release-for-supply procedures for medicinal cannabis in Australia. ECS has obtained all necessary import approvals and is progressing toward the targeted launch window.

Launch efforts will be supported by ECS’s Medical Science Liaison team engaging healthcare professionals, leveraging existing relationships to introduce the new product category. ECS will monitor initial sales and uptake before deciding on subsequent order timing and volume from Ichor Inc. The company anticipates the new range will drive continued growth and diversification of its branded B2C portfolio, with further updates pending material developments in sales or product expansion.

GMP-Certified Australian Manufacturing at ECS Botanics in Victoria

ECS Botanics Holdings Ltd operates as a medicinal cannabis cultivator and manufacturer in Murrabit West, Victoria. Licensed by the Australian Therapeutic Goods Administration, ECS produces GMP-certified products meeting standards equivalent to PIC/S certification recognized by European regulators. The company is known for high-quality, affordable medicinal cannabis, utilizing regenerative and organic horticultural methods combined with renewable energy to ensure sustainable production.

ECS's established distribution infrastructure supports the launch of the OzSun all-in-one vape range, leveraging strong relationships with healthcare practitioners and patients within Australia's prescription medicinal cannabis framework. The company’s focus on quality, affordability, and sustainability positions it as a key player in Australia’s regulated medicinal cannabis sector. The move into larger-format vape products marks a strategic evolution of ECS’s branded portfolio, building on its manufacturing expertise, regulatory compliance, and distribution capabilities.

Branded B2C Portfolio Growth Through Higher-Margin Vape Products

The OzSun all-in-one vape launch underscores ECS's strategy to expand its higher-margin branded business-to-consumer portfolio, which includes the AVANI product line. Introducing the 2g vape format under OzSun diversifies offerings while maintaining gross margins comparable to existing high-margin products. This disciplined portfolio extension leverages ECS’s commercial and distribution infrastructure in Australia to enhance profitability.

The consignment agreement with Ichor Inc enables ECS to introduce new branded products without significant capital outlay, facilitating market testing and scalable ordering based on sales. This model supports portfolio diversification and maximizes value extraction from ECS’s distribution platform without limiting capital for other priorities. ECS views the new range as an opportunity for continued branded portfolio growth, with potential for additional launches or expansions based on market response.

Medicinal Cannabis Market Evolution and Product Category Trends

ECS’s launch of larger-format vape products occurs amid evolving product category development in Australia’s medicinal cannabis market and demonstrated maturity in North American cannabis jurisdictions. International data shows vapes have gained significant penetration in mature markets, with disposable vapes driving category growth. The trend toward larger-format products reflects shifting consumer preferences and practitioner guidance emphasizing value-per-gram and convenience.

Australia’s prescription medicinal cannabis framework offers a regulated environment for product development and supply through qualified healthcare professionals, enabling branded product differentiation and portfolio expansion. ECS’s introduction of a larger-format, integrated vape with native terpene formulations aligns with category trends while complying with Australian therapeutic goods regulations. The OzSun vape launch timing coincides with market maturation, as practitioners and patients seek diverse formats and cannabinoid options for varied therapeutic needs.